Clinical Commissioning Policy Statement: Cerliponase alfa for neuronal ceroid lipofuscinosis Type 2 (CLN2) in Children

Document first published:
Page updated:
Topic:
,
Publication type:

This document sets out NHS England’s policy position in respect of commissioning the drug cerliponase alfa for children who have the rare disease, neuronal ceroid lipofuscinosis type 2.

Summary

NHS England was asked to urgently consider its commissioning position in advance of the drug being appraised by NICE. Based on a limited scoping of the evidence, NHS England has concluded that there is insufficient evidence to support routine commissioning of the drug for this condition.